Abstract Information about the stage of liver
Introduction
Worldwide, approximately 170 million people are infected with chronic hepatitis C (CHC) [1] . Mortality associated with CHC results mainly from the development of fibrosis and subsequent cirrhosis [2] . Accurate staging of liver fibrosis in patients with CHC is important for prognostic information and guides the physician in treatment decisions. Traditionally, the monitoring of fibrosis has been based on histological staging of liver biopsies, a procedure that is both unpleasant for the patient and may have severe side effects [3, 4] . Transient elastography (TE) has, within the last few years, been widely accepted for its excellent diagnostic accuracy for fibrosis and cirrhosis for patients infected with CHC [5] [6] [7] [8] , but this method requires trained staff and it may be difficult to obtain a valid examination in obese patients.
CHC results in a process of inflammation and progressive fibrosis [2] . Pro-inflammatory cytokines and chemokines are involved in this process and the plasma levels of these may be associated with different stages of hepatitis Cassociated liver fibrosis [9, 10] . Although current knowledge about these inflammatory cytokines and chemokines is limited, studies have demonstrated that the plasma levels of some chemokines correlate with liver fibrosis [11] [12] [13] . There is a need for non-invasive, simple, inexpensive, and accurate tools to determine and monitor liver fibrosis in CHC patients. Chemokines, cytokines, and other plasma proteins are easily obtainable from a blood sample and are an attractive possibility.
In this study, we have investigated the potential of using the plasma levels of tumor necrosis factor-α (TNF-α), interleukin 8 (IL-8, CXCL8), interferon-γ inducible protein-10 (IP-10, CXCL10), monocyte chemotactic protein-1 (MCP-1, CCL2), soluble urokinase-type plasminogen activator (suPAR), monokine induced by γ-interferon (MIG, CXCL9), human hepatocyte growth factor (HGF), insulin, interleukin 6 (IL-6), interleukin 1-β (IL-1β), leptin, and nerve growth factor (NGF) for differentiating no/mild liver fibrosis from cirrhosis in patients with CHC genotype 1.
Methods

Patients and samples collection
Patients with CHC genotype 1 (hepatitis C RNA PCRdetectable for more than 6 months) were included in the study if they had no/mild fibrosis or cirrhosis determined by a successful examination with TE. Including only patients with CHC and with no/mild fibrosis or cirrhosis was done in order to have a better probability to detect a correlation between potential markers and the stage of fibrosis in this initial study. Patients were recruited between January 2009 and March 2010 from two Danish clinics specialized in hepatitis. At the time of examination with TE, blood was drawn for hepatitis C RNA detection, platelet counts, analysis of alanine aminotransferase (ALT) and a plasma sample was frozen for the later analysis of potential fibrosis markers. To be able to detect a statistically significant difference between the two groups, we planned to include 40 participants and the study was closed for inclusion when the target of 40 patients was reached.
The study has been approved by the Danish National Committee on Biomedical Research Ethics (H-D-2007-0087) in accordance with the Helsinki Declaration. All patients had given written and oral consent to participate in the study.
Inclusion criteria
Patients older than 18 years of age, with CHC genotype 1, and with no/mild liver fibrosis (<7.7 kPa) or cirrhosis (≥13.0 kPa) were offered participation in the study.
Exclusion criteria
Patients with hepatocellular carcinoma, previous liver transplantation, or liver metastases were not included in the study. Patients co-infected with hepatitis C virus genotypes different from 1, with hepatitis B virus, or with human immunodeficiency virus (HIV) were not offered inclusion in the study. Furthermore, patients were excluded if they had been administered interferon or ribavirin for up to one year before examination. Patients with a selfreported large current daily alcohol consumption (>36 g women,>60 g males) were not included.
Transient elastography
For liver stiffness measurements, we used FibroScan® (Echosens, Paris, France) with a medium probe and software version 1.30. Liver stiffness measurement was considered to be successful if ten valid measurements were obtained (valid measurements>60% and interquartile range <25%). Patients were diagnosed as having no/mild fibrosis when the liver stiffness was below 7.7 kPa, and as having cirrhosis when the values were equal to or above 13.0 kPa. These cut-off values were selected prior to the study and are based on a large meta-analysis including 50 studies of correlation between fibrosis determined by liver biopsy and TE [7] . For diagnosing cirrhosis (F4 Metavir classification) with a cut-off value of 13.0 kPa, a mean area under the receiver operating characteristic curve (AUC) of 0.94 has been shown and for diagnosing significant fibrosis (F2) with liver stiffness above 7.7 kPa, the mean AUC was 0.84 [7] . Liver stiffness measurements were performed by two physicians certified in the use of TE and with experience of more than 300 examinations.
Test methods
Plasma from one 9-ml EDTA-coated tube was separated by centrifugation and stored at −80°C until the fibrosis marker measurements were performed. Blood samples were taken from patients on the same day as the liver stiffness measurement.
All fibrosis markers were measured blinded and in duplicates. Plasma levels of interleukin 1-β, IL-6, IL-8, insulin, HGF, leptin, MCP-1, NGF, and TNF-α were determined per protocol using Luminex xMAP technology (Luminex Corp., Austin, TX, USA) and Milliplex Map Human Serum Adipokine (Panel B) Kit in 1:1 diluted samples (Millipore Corp., St. Charles, MO, USA). Plasma levels of suPAR, IP-10, and MIG were determined with enzyme-linked immunosorbent assays (ELISA) in accordance with the manufacturer's instructions (suPARnostic, ViroGates, Denmark; Quantikine, R&D Systems, MN, USA). IP-10 levels were also determined with an in-house IP-10 ELISA (provided by M. Ruhwald). ELISA of suPAR was done after diluting plasma samples to 1:10, IP-10 after diluting plasma samples to 1:4, and MIG after dilution to 1:1. Measurements were fitted with linear regression analysis. All fibrosis marker concentrations are presented after correcting for dilution.
Statistics
Concentrations of fibrosis markers were compared using non-parametric tests. The diagnostic performance of the markers was determined using ROC curve analysis and compared in accordance with the method suggested by Hanley and McNeil [14] . The data were analyzed using the software package "R Statistics", version 2.9.0 (R Development Core Team, Vienna, Austria) and SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). p-values <0.05 were considered to be significant.
Results
Among the 40 patients included, 21 had cirrhosis and 19 had no/mild fibrosis. The median age was 57 years for the cirrhotic patients versus 46 years for the patients with no/ mild fibrosis. Furthermore, the cirrhotic patients had a median body mass index (BMI) of 26.5 versus 22.6 for the non-cirrhotic patients (Table 1) . Of the 40 patients included, ten had within 5 years of inclusion undergone a percutaneous liver biopsy of a minimum of 10 mm in length containing at least five portal tracts. Local pathologists had independently of this study evaluated the biopsy. Among these patients, 9 (90%) had a fibrosis stage determined by liver biopsy in agreement with the fibrosis stage determined by TE.
Concentrations of the 12 potential fibrosis markers were compared between patients with no/mild fibrosis and cirrhosis. TNF-α, IL-8, IP-10, MCP-1, suPAR, MIG, and HGF were significantly higher in cirrhotic patients compared to patients with no/mild fibrosis. There were no differences in the IP-10 levels measured with the commercial and the in-house ELISA, therefore, only the levels determined with the in-house assay is presented. Concentration levels of the 12 markers for patients with no/mild fibrosis and cirrhosis are shown in Fig. 1 . The ROC curves for TNF-α, IL-8, IP-10, MCP-1, and suPAR are illustrated in Fig. 2 . The fibrosis markers that differentiated best between the two groups were TNF-α (median 15.0 vs. 25.1 pg/ml, AUC 0.91), IL-8 (48.7 vs. 103.3 pg/ml, AUC 0.85), and IP-10 (176 vs. 566 pg/ml, AUC 0.83) ( Table 2 ). There were no significant differences in the AUCs between any of the fibrosis markers that showed significant association with fibrosis stage.
Discussion
The present case-control study shows that plasma levels of TNF-α, IL-8, IP-10, MCP-1, suPAR, MIG, and HGF are significantly higher for cirrhosis than with no/mild fibrosis among patients with CHC genotype 1. Especially, TNF-α, IL-8, and IP-10 show potential as fibrosis markers, as they were consistently expressed in high levels in patients with cirrhosis and not in patients with no/mild fibrosis.
An ideal fibrosis marker should not only have a high sensitivity and specificity, but it must also be easily assessable, inexpensive, accurate, and reproducible. Fibrosis markers from a blood sample are easily obtained and, therefore, an appealing possibility to search for markers to fulfill the remaining criteria. Some of the potential fibrosis markers in this study have been investigated earlier. Moura et al. have recently demonstrated that the plasma concentration of MIG was significantly higher among patients with CHC and moderate fibrosis than with absent/mild fibrosis, but unlike the presented study, they were not able to show any significant difference between plasma levels of IP-10 and MCP-1 for the two groups. This could be due to the fact that Moura et al. compared absent/mild fibrosis with moderate fibrosis (≥F2) instead of cirrhosis combined with a relatively limited number of patients included [13] . In agreement with our findings, MCP-1 and IP-10 have, in other studies, been shown to be associated with the stage of liver fibrosis among patients with CHC [12, 15, 16] . TNF-α seems to be associated with liver inflammation, but another study has also found that TNF-α is also associated with the stage of fibrosis among patients with CHC in correlation with our results [17] [18] [19] . Interestingly, plasma levels of IL-8 seem to be associated with tumor size and stage of hepatocellular carcinoma, which indicates that, besides having potential as a fibrosis marker, IL-8 may also be involved in the progression of hepatocellular carcinoma [20, 21] . Association between plasma levels of HGF for patients with CHC and no/mild fibrosis or cirrhosis have been demonstrated in an earlier study and the findings are in agreement with ours [22] . The association between suPAR and cirrhosis among patients with CHC has not, to our knowledge, been demonstrated earlier. Elevated plasma suPAR level has been associated with faster disease progression and increased risk of mortality in both diseased patients and in the general population [23] . A limitation of the study was that we only demonstrated a binary distinction between no/mild fibrosis and cirrhosis. The possibility of using these markers to differentiate stages of fibrosis could provide additional prognostic information. Furthermore, combining information from several markers may improve the diagnostic accuracy in detecting liver fibrosis. This study was underpowered to investigate a significant effect of combining the investigated fibrosis markers. So far, no combined plasma fibrosis markers have gained universal acceptance, even though several have been proposed, e.g., FibroTest, Forns' Fibrosis Index, and APRI [24] [25] [26] . In this study, we find individual fibrosis markers fully comparable with these indexes, e.g., APRI (with a cutoff of>1.0, AUC 0.89 in training set/0.94 in validation set for diagnosing cirrhosis) and Forns' Fibrosis Index (with a cut-off of>4.2, AUC of 0.86 in estimation group/0.81 validation group for diagnosing significant fibrosis) [24, 26] . A combined fibrosis marker based on some of the markers investigated in this study may be superior to these fibrosis indexes, but further studies are needed.
Several studies have demonstrated a strong correlation between liver stiffness and the stage of fibrosis determined by liver biopsy [5] [6] [7] [8] . Two studies have found that TE is unsuitable for detecting fibrosis in patients with acute hepatitis involving severe inflammation, since this increases liver stiffness [27, 28] . Patients with CHC could potentially have a flare-up in liver inflammation when included in this study, resulting in a higher liver stiffness and causing overestimation of the fibrosis stage. In addition, liver inflammation has been shown to result in higher levels in some chemokines [10, 13] . Severe inflammation could, therefore, give both higher liver stiffness values and plasma levels and be misinterpreted as pronounced liver fibrosis. However, ten of the 40 patients included had also undergone a liver biopsy showing good correlation between fibrosis stages determined by liver biopsy and by TE (90%).
The present study was cross-sectional and, thus, unable to provide information on the potential of the fibrosis marker measurements for monitoring fibrosis changes and prediction of treatment outcome. Recently, studies have demonstrated that one of the investigated fibrosis markers (IP-10) provides prognostic information on treatment outcome in patients mono-infected with CHC as well as HIV/CHC co-infected [29] [30] [31] [32] . In a study with 173 patients with CHC genotype 1 included, the pretreatment IP-10 levels predicted rapid and sustained virological response [32] .
In summary, in a patient sample of 40 individuals, we find that plasma concentrations of TNF-α, IL-8, IP-10, MCP-1, suPAR, MIG, and HGF are significantly higher for cirrhosis than no/mild liver fibrosis in patients infected with CHC genotype 1. Insulin, IL-6, interleukin 1-β, leptin, and NGF do not seem to be significantly correlated to fibrosis in our patient sample. Especially, TNF-α, IL-8, and IP-10 show potential as suitable fibrosis markers, as they were consistently expressed in high levels in patients with advanced fibrosis and not in patients without fibrosis. This study was an initiative study and further prospective studies are needed among patients with CHC to validate the clinical applicability of these fibrosis markers alone or in combination.
